Poor biological factors and prognosis of interval breast cancers: Long-term results of bahçeşehir (Istanbul) breast cancer screening project in Turkey

ArticleAçık Erişim

Özet

PURPOSE The Turkish Bahçeşehir Breast Cancer Screening Project was a 10-year, organized, population-based screening program carried out in Bahçeşehir county, Istanbul. Our aim was to examine the biologic features and outcome of screen-detected and interval breast cancers during the 10-year study period. METHODS Between 2009 and 2019, 2-view mammograms were obtained at 2-year intervals for women aged 40 to 69 years. Clinicopathological characteristics including ER, PR, HER2-neu, and Ki-67 status were analyzed for those diagnosed with breast cancer. RESULTS In 8,758 screened women, 131 breast cancers (1.5%) were detected. The majority of patients (82.3%) had prognostic stage 0-I disease. Contrarily, patients with interval cancers (n = 15; 11.4%) were more likely to have a worse prognostic stage (II-IV disease; odds ratio [OR], 3.59, 95% CI, 0.9 to 14.5) and high Ki-67 scores (OR, 3.14; 95% CI, 0.9 to 11.2). Interval cancers detected within 1 year were more likely to have a luminal B (57.1% v 31.9%) and triple-negative (14.3% v 1%) subtype and less likely to have a luminal A subtype (28.6% v 61.5%; P =.04). Patients with interval cancers had a poor outcome in 10-year disease-specific (DSS) and disease-free survival (DFS) compared with those with screen-detected cancers (DSS: 68.2% v 98.1%, P =.002; DFS: 78.6% v 96.5%, P =.011). CONCLUSION Our findings suggest the majority of screen-detected breast cancers exhibited a luminal A subtype profile with an excellent prognosis. However, interval cancers were more likely to have aggressive subtypes such as luminal B subtype or triple-negative cancers associated with a poor prognosis requiring other preventive strategies. © 2020 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13648Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1200/go.20.00145Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCabioglu, Neslihan
dc.contributor.authorGürdal, Sibel Özkan
dc.contributor.authorKayhan, Arda
dc.contributor.authorÖzaydın, Nilüfer
dc.contributor.authorŞahin, Cennet
dc.contributor.authorCan, Ömür
dc.contributor.authorÖzçınar, Beyza
dc.contributor.authorAykuter, Gönül
dc.contributor.authorVatandaş, Gülçin
dc.contributor.authorAribal, Erkin
dc.contributor.authorÖzmen, Vahit
dc.date.accessioned2026-10-18T20:28:28.943291683Z
dc.date.available2026-10-18T20:28:28.943291683Z
dc.date.issued2020
dc.description.abstractPURPOSE The Turkish Bahçeşehir Breast Cancer Screening Project was a 10-year, organized, population-based screening program carried out in Bahçeşehir county, Istanbul. Our aim was to examine the biologic features and outcome of screen-detected and interval breast cancers during the 10-year study period. METHODS Between 2009 and 2019, 2-view mammograms were obtained at 2-year intervals for women aged 40 to 69 years. Clinicopathological characteristics including ER, PR, HER2-neu, and Ki-67 status were analyzed for those diagnosed with breast cancer. RESULTS In 8,758 screened women, 131 breast cancers (1.5%) were detected. The majority of patients (82.3%) had prognostic stage 0-I disease. Contrarily, patients with interval cancers (n = 15; 11.4%) were more likely to have a worse prognostic stage (II-IV disease; odds ratio [OR], 3.59, 95% CI, 0.9 to 14.5) and high Ki-67 scores (OR, 3.14; 95% CI, 0.9 to 11.2). Interval cancers detected within 1 year were more likely to have a luminal B (57.1% v 31.9%) and triple-negative (14.3% v 1%) subtype and less likely to have a luminal A subtype (28.6% v 61.5%; P =.04). Patients with interval cancers had a poor outcome in 10-year disease-specific (DSS) and disease-free survival (DFS) compared with those with screen-detected cancers (DSS: 68.2% v 98.1%, P =.002; DFS: 78.6% v 96.5%, P =.011). CONCLUSION Our findings suggest the majority of screen-detected breast cancers exhibited a luminal A subtype profile with an excellent prognosis. However, interval cancers were more likely to have aggressive subtypes such as luminal B subtype or triple-negative cancers associated with a poor prognosis requiring other preventive strategies. © 2020 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License
dc.description.sponsorshipSupported by a grant from Roche (V.Ö.) and Basaksehir (Bahçes¸ehir is a region in the Basaksehir county in Istanbul) Municipality.
dc.identifier.doi10.1200/go.20.00145
dc.identifier.endpage1113
dc.identifier.issn2687-8941
dc.identifier.issue6
dc.identifier.pmcidPMC7392766
dc.identifier.pmid32678710
dc.identifier.scopus2-s2.0-85088221747
dc.identifier.startpage1103
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13648
dc.identifier.volume6
dc.language.isoen
dc.publisherAmerican Society of Clinical Oncology
dc.relation.ispartofJCO Global Oncology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiomarkers, Tumor
dc.subjectBreast Neoplasms
dc.subjectEarly Detection of Cancer
dc.subjectFemale
dc.subjectHumans
dc.subjectPrognosis
dc.subjectTurkey
dc.subjectepidermal growth factor receptor 2
dc.subjectestrogen receptor
dc.subjectKi 67 antigen
dc.subjectprogesterone receptor
dc.subjecttumor marker
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectbreast cancer
dc.subjectcancer diagnosis
dc.subjectcancer prognosis
dc.subjectcancer screening
dc.subjectcancer staging
dc.subjectcontrolled study
dc.subjectdisease free survival
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmammography
dc.subjectmiddle aged
dc.subjectpriority journal
dc.subjectTurkey (republic)
dc.subjectbreast tumor
dc.subjectearly cancer diagnosis
dc.titlePoor biological factors and prognosis of interval breast cancers: Long-term results of bahçeşehir (Istanbul) breast cancer screening project in Turkey
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus4
rdl.departmentDepartment of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexPUBMED